Clinical trials: Elderly Immune Senescence
Dermatitis Atopic
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
This is a single group, 1-arm, long-term safety study for treatment of participants with moderate to severe atopic dermatitis (AD).
- Trial name
- ATLANTIS (NCT05769777)
- Testing
- Amlitelimab
- Where
- 174 sites in United States, Argentina and 23 more
- Volunteers
- 999 people
- Sponsor
- Sanofi
Human Papillomavirus Infection
Long-term Immune Persistence of a Bivalent HPV Vaccine in Females From Study 311-HPV-1004
This long-term extension study evaluates the persistence of neutralizing antibody responses to a bivalent human papillomavirus vaccine in females who previously participated in study 311-HPV-1004 (NCT02740777).
- Trial name
- NCT07820241
- Testing
- Bivalent Human Papillomavirus Vaccine (Types 16 and 18, Pichia pastoris)
- Where
- 2 sites in China
- Volunteers
- 348 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
Chronic Lymphocytic Leukemia
Fludarabine or Chlorambucil as First-Line Therapy in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy, such as fludarabine and chlorambucil, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00262795
- Testing
- Fludarabine, Chlorambucil
- Where
- 88 sites in Austria, Germany
- Volunteers
- 206 people
- Sponsor
- German CLL Study Group
Asthma
The Predictors for Asthma Control by Stepwise Treatment During 6 Months in Korean Elderly
The Predictors for asthma control by stepwise treatment during 6 months in Korean elderly
- Trial name
- Prelude (NCT01370577)
- Where
- 5 sites in South Korea
- Volunteers
- 297 people
- Sponsor
- AstraZeneca
Aging
Effect of mTOR Inhibition & Other Metabolism Modulating Interventions on the Elderly [SubStudy Rapa & cMRI to Evaluate Cardiac Function]
The ability to mount an effective immune response declines with age, leaving the elderly increasingly susceptible to infectious diseases and cancer.
- Trial name
- mTOR (NCT04742777)
- Testing
- rapamycin
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Late Effects, Testicular Germ Cell Tumor Mixed
A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Survivors.
INTRODUCTION: Approximately 44% of cancer survivors experience a deteriorated quality of life 5 years after diagnosis due to late onset of complications related to cancer treatments.
- Conditions
- Late Effects, Testicular Germ Cell Tumor Mixed, Non-Metastatic Breast Carcinoma, Soft Tissue Sarcoma, Adult, Stage IIC
- Trial name
- PASCA (NCT04671693)
- Testing
- PASCA intervention
- Where
- France
- Volunteers
- 500 people
- Sponsor
- Centre Leon Berard
Type 1 Diabetes, Eating Disorder
Develop and Validate a Self-Administered Instrument That Will Screen for Eating Disorder Symptoms in Persons Aged 12 and Older With Type 1 Diabetes.
The purpose of this study is to develop and validate a survey instrument to be used by persons with type 1 diabetes aged 12 and older to screen for an eating disorder.
- Trial name
- NCT00948311
- Where
- United States
- Volunteers
- 279 people
- Sponsor
- HealthPartners Institute
Diffuse Large-Cell Lymphoma
ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients With Diffuse Large B-cell Lymphoma and Age-adjusted IPI of 1
This study is a multicentric randomized trial evaluating the efficacy of the combination ACVBP+rituximab compared to the combination of CHOP+rituximab in patients aged from 18 to 59 years with diffuse large B-cell lymphoma and…
- Trial name
- NCT00140595
- Testing
- rituximab, doxorubicin, cyclophosphamide
- Where
- 10 sites in Belgium, France
- Volunteers
- 380 people
- Sponsor
- Lymphoma Study Association
Respiratory Syncytial Virus Infections
A Study on the Immune Response, Safety and the Occurrence of Respiratory Syncytial Virus (RSV)-Associated Respiratory Tract Illness After Administration of RSV OA Vaccine in Adults 60 Years and Older
The purpose of the current study is to evaluate the immune response of the RSVPreF3 OA investigational vaccine in older adults (OA) at least (>=) 60 years of age (YOA) in China compared to OA in the same age range to be enrolled…
- Trial name
- NCT06551181
- Testing
- RSVPreF3 OA investigational vaccine
- Where
- 40 sites in China, Finland and 5 more
- Volunteers
- 2,620 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hypersensitivity
A Study to Learn More About the Safety of Ultravist in Children and in the Elderly
Ultravist is an iodine-based contrast agent that helps to make medical imaging scans clearer. It is also called iopromide, and it is available for doctors to give patients before they have scans.
- Trial name
- NCT04605471
- Testing
- Iopromide(Ultravist, BAY86-4877)
- Where
- Germany
- Volunteers
- 132,850 people
- Sponsor
- Bayer
Lymphocytic Leukemia, Chronic
A Study of MabThera/Rituxan (Rituximab) in Combination With Fludarabine And Cyclophosphamide as Primary Therapy in Elderly Patients With Chronic Lymphocytic Leukemia
This single arm, open-label study will assess the safety and efficacy of low dose fludarabine and cyclophosphamide in combination with standard dose MabThera/Rituxan (rituximab) as primary therapy in elderly patients (>/= 65…
- Trial name
- NCT01263704
- Testing
- Cyclophosphamide, Fludarabine, Rituximab
- Where
- 12 sites in Israel
- Volunteers
- 42 people
- Sponsor
- Hoffmann-La Roche
Multiple Myeloma
Tandem Melphalan and Autolog. SCT in MM Patients 60 to 70 Years of Age With and Without Induction Chemotherapy
Patients 60 to 70 years of age with newly diagnosed multiple myeloma were prospectively randomized between 4 cycles of anthracycline/dexamethasone-based induction chemotherapy (A1) or only 2 x 4 days of dexamethasone (A2).
- Trial name
- DSMM-II (NCT02288741)
- Testing
- Anthracycline/dexamethasone-based induction chemotherapy, Dexamethasone for control of symptoms, Tumor-reduction chemotherapy and stem cell mobilization
- Volunteers
- 549 people
- Sponsor
- WiSP Wissenschaftlicher Service Pharma GmbH
Insulin Resistance, Metabolic Syndrome X
Description of an Immune Activation Profile Linked to Insulin Resistance in Subjects Aged 55-69
The aim of the study is to describe an immune activation profile of people at risk of insulin resistance based on a wide range of markers which will allow easy identification of patients at risk.
- Trial name
- METACTIV (NCT03309761)
- Testing
- Blood test
- Where
- 2 sites in France
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Lymphoma
Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma
RATIONALE: Monoclonal antibodies such as rituximab and yttrium Y 90 ibritumomab tiuxetan can locate cancer cells and either kill them or deliver radioactive cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00058422
- Testing
- darbepoetin alfa, filgrastim, rituximab
- Where
- 2 sites in United States
- Volunteers
- 65 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Innate Immunity, Bacille Calmette-Guérin
Testing if BCG (Bacille Calmette-Guérin) Vaccination Can Induce Innate Immune Training in Adult People Above 50 Years of Age in Guinea-Bissau
The propose is to test innate immune training in a pilot study of 40 adults >50 years of age people in Guinea-Bissau. The hypothesis is that BCG vaccination will be associated with increased innate immune training measured as…
- Trial name
- NCT02953327
- Testing
- Bacille Calmette-Guerin, BCG solvent
- Where
- Guinea-Bissau
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bandim Health Project
Lymphoma
Diffuse Large B Cell Non-Hodgkin's Lymphoma in the Vulnerable/Frail Elderly. A Multicentric Randomized Phase II Trial
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- FRAIL-06 (NCT00911183)
- Testing
- filgrastim, pegfilgrastim, rituximab
- Where
- France
- Volunteers
- 67 people
- Sponsor
- Institut Bergonié
Cognitive Decline, Mild
Predict Early Cognitive Changes in a Healthy Elderly Population by Passively Recording Sensor Data From Mobile Devices
The study will recruit 100 participants aged 65+ residing in assisted living facilities. Eligible participants will undergo an initial cognitive assessment to document their baseline cognitive status using cognitive tests…
- Trial name
- 0150-24 SOR (NCT07596186)
- Where
- Israel
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Soroka University Medical Center
Hypercholesterolemia, Hyperbilirubinemia
Study of Efficacy and Safety of the Plasmapheresis Method With Albumin Compensation Compared With the Plasmapheresis Method Without Albumin Compensation for Aging Biomarkers Correction in Men and Women Aged 40 to 55 Years Old
Reaching active aging makes it important to implement new methods affecting the biological age of a person. Biochemical parameters of a blood test are aging biomarkers that are ones of the most accessible for testing.
- Conditions
- Hypercholesterolemia, Hyperbilirubinemia, Hyper IgE Syndrome, Hyper Beta Lipoproteinemia
- Trial name
- NCT04897113
- Testing
- plasma exchange with albumin, plasma exchange without albumin
- Where
- 2 sites in Russia
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- National Medical Research Center for Rehabilitation and Balneology
Asthma
A Study of MK0476 in the Treatment of Asthma Patients Aged 2-5 Years (0476-907)
A study to determine the efficacy of MK0476 in the Treatment of Asthmatic Patients Aged 2 to 5 Years.
- Trial name
- NCT00700661
- Testing
- montelukast
- Volunteers
- 500 people
- Sponsor
- Organon and Co
Dermatitis, Atopic
Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis
B7451012 is a Phase 3 study to evaluate PF-04965842 in patients aged 12 years and older with a minimum body weight of 40 kg who have moderate to severe atopic dermatitis.
- Trial name
- JADE Mono-1 (NCT03349060)
- Testing
- PF-04965842 100 mg, PF-04965842 200 mg
- Where
- 88 sites in United States, Australia and 6 more
- Volunteers
- 387 people
- Sponsor
- Pfizer